In-Hospital Mortality Risk Factor Analysis in Multivessel Percutaneous Coronary Intervention Inpatient Recipients in the United States

Ravi Tummala 1, Suchi D. Shah 2, Iza Rawal 3, Ramneek K. Sandhu 4, Swathi P. Kavuri 5, Gagan Kaur 6, Asma T. Khan 7, Keerthika Mathialagan 8, Temitope Ajibawo 9

1. Internal Medicine, Narayana Medical College, Nellore, IND 2. Internal Medicine, Ahmedabad Municipal Corporation's Medical Education Trust Medical College, Ahmedabad, IND 3. Cardiology, Norvic International Hospital, Kathmandu, NPL 4. Internal Medicine, Sri Guru Ram Das Institute of Medical Sciences and Research, Amritsar, IND 5. Internal Medicine, Sri Ramachandra Institute of Higher Education and Research, Chennai, IND 6. Surgery, Sri Guru Ram Das Institute of Medical Sciences and Research, Amritsar, IND 7. Internal Medicine, Larkin Community Hospital, South Miami, USA 8. Psychiatry, Sree Balaji Medical College and Hospital, Chennai, IND 9. Internal Medicine, Brookdale University Hospital Medical Center, New York City, USA

Corresponding author: Keerthika Mathialagan, keerthim27@outlook.com

Abstract

Introduction

Objectives

Methods

The primary goal of our study is to evaluate the mortality rate in inpatient recipients of multivessel percutaneous coronary intervention (MVPCI) and to evaluate the demographic risk factors and medical complications that increase the risk of in-hospital mortality.

We conducted a cross-sectional study using the Nationwide Inpatient Sample (NIS, 2016) and included 127,145 inpatients who received MVPCI as a primary procedure in United States' hospitals. We used a multivariable logistic regression model adjusted for demographic confounders to measure the odds ratio (OR) of association of medical complications and in-hospital mortality risk in MVPCI recipients. Accelerated use of MVPCI made it important to study in-hospital mortality risk factors allowing us to devise strategies to improve the utilization and improve the quality of life of these at-risk patients. Despite its effectiveness and comparatively lower mortality profile, aggressive usage of MVPCI is restricted due to the periprocedural complications and morbidity profile of the patients.

Methods

We conducted a cross-sectional study using the Nationwide Inpatient Sample (NIS, 2016) and included 127,145 inpatients who received MVPCI as a primary procedure in United States' hospitals. We used a multivariable logistic regression model adjusted for demographic confounders to measure the odds ratio (OR) of association of medical complications and in-hospital mortality risk in MVPCI recipients.

Results

The in-hospital mortality rate was 2% in MVPCI recipients and was seen majorly in older-age adults (>64 years, 74%) and males (61%). Even though the prevalence of mortality among females was comparatively low, yet in the regression model, they were at a higher risk for in-hospital mortality than males (OR 1.2; 95% CI 1.13-1.37). While comparing ethnicities, in-hospital mortality was prevalent in whites (79%) followed by blacks (9%) and Hispanics (7.5%). Patients who developed cardiogenic shock were at higher odds of in-hospital mortality (OR 9.2; 95% CI 8.27-10.24) followed by respiratory failure (OR 5.9; 95% CI 5.39-6.64) and ventricular fibrillation (OR 3.5; 95% CI 3.18-3.92).

Conclusion

Accelerated use of MVPCI made it important to study in-hospital mortality risk factors allowing us to devise strategies to improve the utilization and improve the quality of life of these at-risk patients. Despite its effectiveness and comparatively lower mortality profile, aggressive usage of MVPCI is restricted due to the periprocedural complications and morbidity profile of the patients.
an integral part in MVPCI utilization. Among the ethnic minorities, blacks are the least likely to utilize resources like PCI or coronary artery bypass graft (CABG), where differences in clinical presentation and physicians’ bias in treating minorities contribute to the discrepancy [6].

Patients undergoing MVPCI have baseline comorbidities, most notably hypertension and diabetes. However, the percentage of MVPCI utilization in diabetic patients decreased by 40.5% from 2006 to 2012 [7]. The drastic decrease in the utilization of MVPCI is due to a higher mortality rate compared with CABG. However, in other instances, MVPCI is similar in efficacy to PCI, and reclassification of treatment in 2015 by the cardiology board has led to further use [7].

However, like any medical intervention, PCI does pose certain risks of morbidity and mortality. Early complications of MVPCI are stent thrombosis, bleeding, coronary dissection, and renal failure. Late complications are complications of coronary heart disease. The Cleveland Clinic institutional PCI registry report found that 2% of mortality post-PCI occurred within the first 30 days. Of these deaths, 58% died of cardiac and 42% of non-cardiac causes. Interestingly, less than half (42%) of 30-day deaths were attributed to PCI-related complications [8]. Another study found that the major causes of death within the first 30 days after undergoing PCI were cardiogenic shock and anoxic brain injury post-cardiac arrest [9]. However, MVPCI in patients with cardiogenic shock following AMI had a significantly better one-year outcome (21.3%) than patients undergoing single-vessel PCI (31.7%) [10]. Age, culprit vessel size and flow, and the presence of heart failure and diabetes were determined to be risk factors and independent predictors of mortality [11].

So, we conducted a cross-sectional inpatient study to evaluate the mortality rate in patients hospitalized and managed with MVPCI and to evaluate the demographic predictors and medical conditions that increase the risk of in-hospital mortality in MVPCI recipients.

Materials And Methods

Study sample

We conducted a cross-sectional study using the Nationwide Inpatient Sample (NIS) from January 1 to December 31, 2016. We were not required to take the institutional review board’s permission for this study as the NIS is a de-identified publicly available dataset and protects any health-related patient information [12]. We included 127,145 adult patients who were hospitalized and were undergoing MVPCI treatment as the primary procedure.

Variables

Demographic variables included were age at admission (<44, 45-64, or >64 years), sex (male or female), and race/ethnicity (white, black, Hispanic, or others). Comorbid medical complications included in the study are cardiogenic shock, ventricular fibrillation (VFib), respiratory failure, intracranial hemorrhage (ICH), periprocedural stroke, acute kidney injury (AKI), and acute gastrointestinal (GI) bleeding. Our primary hospital outcome is in-hospital mortality, which is all-cause mortality in the NIS [13].

Statistical analysis

We compared the distributions of demographic characteristics, and comorbid medical complications by in-hospital mortality using descriptive statistics and Pearson’s chi-square test. Next, we used a logistic regression model adjusted for demographic confounders to measure the odds ratio (OR) of association of comorbid medical complications and in-hospital mortality risk in inpatients undergoing MVPCI. All analyses were conducted using SPSS Statistics v. 26.0 (IBM Corp., Armonk, NY) and statistical significance was set at a two-sided P-value <0.05.

Results

We included 127,145 medical inpatients who underwent MVPCI as a primary procedure during hospitalization; the in-hospital mortality rate was 1.88%. A higher proportion of these inpatients who died during hospitalization were older-age adults above 64 years of age (74.4%) and males (60.8%). While comparing ethnicities, in-hospital mortality was most prevalent in whites (79.0%), subsequently blacks (8.8%), Hispanics (7.5%), and other races (4.6%). The most prevalent comorbid medical complications among patients who died during hospitalization were a respiratory failure (60%), followed by AKI (53.2%), cardiogenic shock (49.9%), and VFib (37.5%) as shown in Table 1.
TABLE 1: Distribution of inpatients undergoing multivessel percutaneous intervention by in-hospital mortality

| Variable                        | In-hospital mortality | P-value |
|--------------------------------|-----------------------|---------|
|                                | No (in %)             | Yes (in %) |        |
| Number of inpatients           | 124,760               | 2,385   |        |
| Age at admission               |                       |         |        |
| <44 years                      | 5.2                   | 2.3     |        |
| 45-64 years                    | 41.2                  | 23.3    | <0.001 |
| >64 years                      | 53.7                  | 74.4    |        |
| Sex                            |                       |         |        |
| Male                           | 64.4                  | 60.8    | <0.001 |
| Female                         | 35.6                  | 39.2    |        |
| Race                           |                       |         |        |
| White                          | 75.4                  | 79.0    |        |
| Black                          | 10.4                  | 8.8     | <0.001 |
| Hispanic                       | 7.5                   | 7.5     |        |
| Others                         | 6.8                   | 4.6     |        |
| Comorbid medical complications |                       |         |        |
| Cardiogenic shock              | 2.6                   | 49.9    | <0.001 |
| Ventricular fibrillation       | 7.2                   | 37.3    | <0.001 |
| Respiratory failure            | 6.3                   | 60.0    | <0.001 |
| Acute kidney injury            | 13.6                  | 53.2    | <0.001 |
| Acute gastrointestinal bleeding| 0.5                   | 5.7     | <0.001 |
| Periprocedural stroke          | 0                     | 0.2     | 0.02   |
| Intracranial hemorrhage        | 0                     | 0       |        |

Even though the prevalence of in-hospital mortality among females was comparatively low, females were at a higher risk of mortality than males (OR 1.24; 95% CI 1.13–1.37). Compared to the white population, other races/ethnicities had a lower and non-significant association with in-hospital mortality.

There existed a statistically significant association between certain risk factors and in-hospital mortality. Patients who developed cardiogenic shock were at higher odds of mortality (OR 9.20; 95% CI 8.27–10.24), followed by respiratory failure (OR 5.99; 95% CI 5.39–6.64), acute gastrointestinal (GI) bleeding (OR 3.67; 95% CI 2.83–4.75), VFib (OR 3.53; 95% CI 3.18–3.92), and AKI (OR 2.49; 95% CI 2.26–2.75) as shown in Table 2.
## TABLE 2: In-hospital mortality risk predictors in inpatients undergoing multivessel percutaneous intervention

| Variable                              | Logistic regression model | P-value |
|---------------------------------------|---------------------------|---------|
|                                       | Odds ratio | 95% confidence interval |
| Age at admission                      |            |                       |
| <44 years                             | Reference   |                       |
| 45-64 years                           | 0.99        | 0.73-1.36              | 0.988   |
| >64 years                             | 2.44        | 1.80-3.31              | <0.001  |
| Sex                                   |            |                       |
| Male                                  | Reference   |                       |
| Female                                | 1.24        | 1.13-1.37              | <0.001  |
| Race                                  |            |                       |
| White                                 | Reference   |                       |
| Black                                 | 0.94        | 0.79-1.11              | 0.471   |
| Hispanic                              | 1.12        | 0.93-1.33              | 0.229   |
| Others                                | 0.62        | 0.49-0.77              | <0.001  |
| Comorbid medical complications        |            |                       |
| Cardiogenic shock                     | 9.20        | 8.27-10.24             | <0.001  |
| Ventricular fibrillation              | 3.53        | 3.18-3.92              | <0.001  |
| Respiratory failure                   | 5.99        | 5.39-6.64              | <0.001  |
| Acute kidney injury                   | 2.49        | 2.26-2.75              | <0.001  |
| Acute gastrointestinal bleeding       | 3.67        | 2.83-4.75              | <0.001  |
| Periprocedural stroke                 | 8.95        | 1.15-69.52             | 0.036   |
| Intracranial hemorrhage               | -           | -                     |         |

**Discussion**

In our comprehensive analysis study of 127,145 inpatient recipients of MVPCI, we determined demographic predictors (age, gender, and race) and medical risk factors that increase the risk of in-hospital mortality. Several papers have already shown the mortality in MVPCI is comparable or even lower than that of post-PCI mortality. Our study further analyzes the potential benefits of MVPCI by assessing in-hospital mortality in the demographic and comorbidity subcategories.

Whites had the highest in-hospital mortality rate in our study inpatients. An observational study in 2019 evaluated race and gender disparities in MVPCI outcomes and resource utilization. Two important conclusions that they made were that the black population had the highest prevalence of comorbidities and Asian women had the highest risk of in-hospital mortality, with rates of in-hospital morbidities increasing yearly with the largest increment in the Hispanic population [6]. Contrary to past findings, we found post-MVPCI hospitalizations more prevalent in whites, which could be due to higher utilization of cardiovascular procedures in general among this population [14].

In-hospital mortality was significantly higher in females by 24% compared to males. Females tend to have a higher mean low-density lipoprotein (LDL) than men because of physiologically higher estrogen levels, wider use of hormonal contraceptives, and hormone replacement therapy contributing to a higher comorbid profile [15]. Other factors like smaller body size, limited access to the quality of care, and inadequate usage of cardioprotective medicines could also contribute to the discrepancy [16]. Gender disparities in terms of preference for cardiovascular testing have also led to seeking healthcare at an advanced stage of the disease, which can directly alter the mortality with reperfusion [17].
Advanced age is a universal predictor of death in cardiovascular diseases and procedures [18]. The extensive coronary atherosclerosis, physiological stiffening leading to decreased left ventricular systolic and diastolic function, and tortuous vascular anatomy pose an added risk. A higher baseline comorbidity profile and impaired age-related compensation make it a treatment-risk paradox [19]. We do not have proper data of their pre-existing comorbid profile, but studies show significant improvement with emergency revascularization (utilizing MVPCI) for mitigation of complications, especially in global diffuse coronary artery disease [20].

A recent meta-analysis confirms that multivessel disease is common in ST-elevated myocardial infarction (STEMI) patients [21]. Theoretically, MVPCI can reperfuse hibernating and stunned myocardium, thereby improving ventricular function. However, our study shows an increased association with mortality. It could be due to increased procedural time, contrast use, and inflammatory milieu due to hemodynamic insult [22]. Studying the outcomes of MVPCI can help devise strategies to treat versus not to treat non-culprit vessels. Untreated non-culprit vessels can lead to long-term rehospitalization, especially for subsequent revascularization for heart failure [23].

Our study shows that VFib was an important risk factor for mortality, owing to the prothrombotic and proinflammatory nature of an acute disease like STEMI [24]. Global reperfusion would help in alleviating any future infarction due to the instability of the lesion. But it is a double-edged sword as it depends on many factors like onset to balloon time, levels of b-type natriuretic peptide, sympathetic tone, elevated lactate/phosphate levels, and many more factors [25]. This again suggests that it is an interplay, and hence reperfusion cannot be a standalone factor for mortality [26].

Periprocedural stroke is clinically significant and a disabling risk factor for mortality due to microembolisms leading to anoxic brain injury. Increased contrast load and multiple ischemic insults due to shock led to renal failure as well. Our study confirms that GI bleed was one of the significant and probably preventable causes of mortality following MVPCI. Pre-existing peptic ulcer disease (PUD), increased vagal stimulation following shock causing ulcers that bleed off, and concomitant usage of antiplatelet therapy could be risk factors besides physiological stress to GI mucosa [27].

There are certain limitations associated with the study conducted. Firstly, this is a cross-sectional study and thus it is hard to establish causal relationships for in-hospital mortality risk, and it is reported all-cause in the NIS. Furthermore, the database does not contain in-depth patient-level clinical information, and in this study, the relevant data were extracted using diagnostic codes, which may have caused the under-reporting of comorbidities. Yet, there are some strengths of this study. NIS database is a large inpatient population data that lead to uniform patient records and provide a population-based perception of mortality associated with systematic and temporal factors. Further, the information is coded independently by the individual physicians, which protects it from reporting bias.

Conclusions

Accelerated use of MVPCI made it important to study in-hospital mortality risk factors allowing us to devise strategies to improve the utilization and improve the quality of life of these at-risk patients. The highest in-hospital mortality following MVPCI was among females and whites. MVPCI inpatients with medical complications had a higher risk of mortality, with cardiogenic shock posing the highest risk (increased by nine times), followed by respiratory failure (increased by six times), and VFib (increased by 3.5 times). Despite its effectiveness and comparatively lower mortality profile, aggressive usage of MVPCI is restricted due to the periprocedural complications and morbidity profile of the patients.

Additional Information

Disclosures

Human subjects: Consent was obtained or waived by all participants in this study. Animal subjects: All authors have confirmed that this study did not involve animal subjects or tissue. Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.

References

1. Benjamin EJ, Blaha MJ, Chiuve SE, et al.: Heart disease and stroke statistics-2017 update: a report from the American Heart Association. Circulation. 2017, 135:e146-603. 10.1161/CIR.0000000000000485
2. Park SH: Percutaneous coronary intervention. J Korean Med Assoc. 2002, 45:567-74. 10.5124/jkma.2002.45.5.567
3. Mohr FW, Morice MC, Kappetein AP, et al.: Coronary artery bypass graft surgery versus percutaneous coronary intervention in patients with three-vessel disease and left main coronary disease: 5-year follow-up.
of the randomised, clinical SYNTAX trial. Lancet. 2015, 381:629-38. 10.1016/s0140-6736(15)60141-5
4. Langabeer JR, Henry TD, Kereiakes DJ, et al.: Growth in percutaneous coronary intervention capacity relative to population and disease prevalence. J Am Heart Assoc. 2015, 2:e000370. 10.1161/JAHA.115.000370
5. Movahed MR, Ramaraj R, Jamal MM, Hashemzadeh M: Nationwide trends in the utilization of multivessel percutaneous coronary intervention (MVPCI) in the United States across different gender and ethnicities. J Interv Cardiol. 2009, 22:247-51. 10.1111/j.1540-8183.2009.00467.x
6. Desai R, Singh S, Fong HK, et al.: Racial and sex disparities in resource utilization and outcomes of multivessel percutaneous coronary intervention patients with STEMI and multivessel disease: the Cardiovasc Diagn Ther. 2019, 9:18-29. 10.21037/cdt.2018.09.02
7. Abosara A, Zheng S, Cao Y, et al.: TCT-480 national trend in multivessel percutaneous coronary intervention in patients with diabetes mellitus in the United States. J Am Coll Cardiol. 2015, 66:B196. 10.1016/j.jacc.2015.08.496
8. Aggarwal B, Ellis SG, Lincoff AM, et al.: Cause of death within 30 days of percutaneous coronary intervention in an era of mandatory outcome reporting. J Am Coll Cardiol. 2015, 62:409-15. 10.1016/j.jacc.2015.05.071
9. Pedersen F, Buttrymovich V, Kelbæk H, et al.: Short- and long-term cause of death in patients treated with primary PCI for STEMI. J Am Coll Cardiol. 2014, 64:2101-8. 10.1016/j.jacc.2014.08.037
10. Henríques JP, Claessen BE: Revascularization strategies in cardiogenic shock patients with MVD: for now, keep it simple. J Am Coll Cardiol. 2018, 71:857-9. 10.1016/j.jacc.2017.12.026
11. Blankenship JC, Marshall JJ, Pinto DS, et al.: Effect of percutaneous coronary intervention on quality of life: a consensus statement from the Society for Cardiovascular Angiography and Interventions. Catheter Cardiovasc Interv. 2015, 81:245-59. 10.1002/ccd.24576
12. Overview of the National (Nationwide) Inpatient Sample. (2021). Accessed: May 1, 2021: https://www.hcup-us.ahrq.gov/nisoverview.jsp.
13. NIS description of data elements. (2021). Accessed: April 18, 2021: https://www.hcup-us.ahrq.gov/db/nation/nis/nisdde.jsp.
14. Rumsfeld JS, Epstein AJ: Racial disparities in cardiovascular procedure outcomes: turn down the volume. J Am Coll Cardiol. 2006, 47:425-6. 10.1016/j.jacc.2005.10.025
15. Boardman HM, Hartley L, Eisinga A, et al.: Hormone therapy for preventing cardiovascular disease in postmenopausal women. Cochrane Database Syst Rev. 2015, CD002229. 10.1002/14651858.CD002229.pub4
16. Butala S, Lewin AM, Simpson SH, et al.: Sex-based disparities in cardioprotective medication use in adults with diabetes. Diabetol Metab Syndr. 2014, 6:117. 10.1186/1758-5996-6-117
17. Golden KE, Chang AM, Hollander JE: Sex preferences in cardiovascular testing: the contribution of the patient-physician discussion. Acad Emerg Med. 2013, 20:680-8. 10.1111/acem.12169
18. Shanmugasundaram M: Percutaneous coronary intervention in elderly patients: is it beneficial? Tex Heart Inst J. 2011, 38:598-405.
19. Yandre M, Tomiyama H, Hirayama Y, et al.: Arterial stiffening as a possible risk factor for both atherosclerosis and diastolic heart failure. Hypertens Res. 2004, 27:625-51. 10.1291/hypres.27.625
20. Chivasso P, Benedetto U: Coronary surgery in elderly: it is never too late. J Thorac Dis. 2016, 8:e1641-3. 10.21037/jtd.2016.12.34
21. Park DW, Clare RM, Schulte PJ, et al.: Extent, location, and clinical significance of non-infarct-related coronary artery disease among patients with ST-elevation myocardial infarction. JAMA. 2014, 312:2019-27. 10.1001/jama.2014.15095
22. Hu MJ, Li XS, Jin C, Yang YJ: Does multivessel revascularization fit all patients with STEMI and multivessel coronary artery disease? A systematic review and meta-analysis. Int J Cardiol Heart Vasc. 2021, 35:100813. 10.1016/j.ijchv.2021.100813
23. Lee JM, Rhee TM, Kim HK, et al.: Comparison of long-term clinical outcome between multivessel percutaneous coronary intervention versus infarct-related artery-only revascularization for patients with ST-segment-elevation myocardial infarction with cardiogenic shock. J Am Heart Assoc. 2019, 8:e015870. 10.1161/JAHA.119.013870
24. Klingenberg R, Brokopp CE, Grives A, et al.: Clonal restriction and predominance of regulatory T cells in coronary thrombi of patients with acute coronary syndromes. Eur Heart J. 2015, 36:1041-8. 10.1093/eurheartj/ehv545
25. Takada T, Shishido K, Hayashi T, et al.: Impact of late ventricular arrhythmias on cardiac mortality in patients with acute myocardial infarction. J Interv Cardiol. 2019, 2019:5545178. 10.1155/2019/5545178
26. Gershlick AH, Khan JN, Kelly DJ, et al.: Randomized trial of complete versus lesion-only revascularization in patients undergoing primary percutaneous coronary intervention for STEMI and multivessel disease: the CVLPRIT trial. J Am Coll Cardiol. 2015, 65:963-72. 10.1016/j.jacc.2014.12.038
27. Tanigawa T, Watanabe T, Nadatani Y, et al.: Gastrointestinal bleeding after percutaneous coronary intervention. Digestion. 2011, 83:153-60. 10.1159/000321813